has been cited by the following article(s):
|
[1]
|
An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation
Pharmaceutics,
2024
DOI:10.3390/pharmaceutics16040517
|
|
|
|
|
[2]
|
An Overview of the Pharmacokinetics and Pharmacodynamics of Landiolol (an Ultra-Short Acting β1 Selective Antagonist) in Atrial Fibrillation
Pharmaceutics,
2024
DOI:10.3390/pharmaceutics16040517
|
|
|
|
|
[3]
|
Landiolol for managing post-operative atrial fibrillation
European Heart Journal Supplements,
2018
DOI:10.1093/eurheartj/sux036
|
|
|
|
|
[4]
|
Perioperative Landiolol Infusion Reduces the Incidence of Atrial Fibrillation after Pulmonary Lobectomy: Postoperative Randomized Controlled Study
Open Journal of Anesthesiology,
2016
DOI:10.4236/ojanes.2016.68020
|
|
|
|